Home LiteratureArticle Details
PMID: 17654662 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.

Cancer ·Vol. 110 ·No. 6 ·2007-09-15 ·Pages 1227-34

Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, Talamonti MS

Abstract

Despite decreased perioperative morbidity and mortality and clinical trials suggesting improved outcomes with adjuvant therapy, national practice patterns in the management of pancreatic cancer remain poorly defined. The purpose of the current study was to evaluate multimodality therapy utilization and outcomes relative to hospital type and volume. Using the National Cancer Data Base, stage-specific treatment patterns were analyzed for 301,033 patients with pancreatic adenocarcinoma. Logistic regression was used to evaluate treatment utilization. Cox proportional hazards modeling was utilized to evaluate the effect of multimodality therapy on survival. Stage at presentation did not differ from 1985-1994 to 1995-2003; however, the percentage of patients receiving cancer-directed treatment increased from 45.1% to 51.8% (P < .001). Pancreatectomy for localized disease (AJCC 6th edition stages I and II) increased from 36.9% to 49.3% (P < .001). After resection, the use of adjuvant chemotherapy alone increased from 4.1% to 5.7% (P < .001), but the use of adjuvant radiation alone decreased from 7.0% to 4.6% (P < .001). Adjuvant chemoradiation use increased from 26.8% to 38.7% (P < .001). The use of surgery alone decreased from 62.1% (5213 of 8400 cases) to 49.9% (10,807 of 21,679 cases) (P < .001). Patients with localized pancreatic cancer were more likely to receive pancreatectomy and adjuvant chemoradiation at academic and high-volume centers (P < .001). Survival for localized disease was better after surgery with adjuvant therapy (hazards ratio [HR], 0.44; 95% confidence interval [95% CI], 0.42-0.47) and surgical resection alone (HR, 0.54; 95% CI, 0.52-0.57) compared with no treatment. To the authors' knowledge, the current study is the largest study regarding pancreatic cancer performed to date, and the first to investigate national practice patterns for multimodality therapy utilization. Multimodality therapy utilization has increased over time and appears to have a beneficial impact on survival.

MeSH Terms
Academic Medical Centers Adenocarcinoma/drug therapy,pathology,radiotherapy,surgery,therapy Aged Aged, 80 and over Chemotherapy, Adjuvant/statistics & numerical data Female Hospital Bed Capacity Humans Logistic Models Male Middle Aged Neoplasm Staging Odds Ratio Pancreatectomy Pancreatic Neoplasms/drug therapy,pathology,radiotherapy,surgery,therapy Predictive Value of Tests Proportional Hazards Models Radiotherapy, Adjuvant/statistics & numerical data Research Design Survival Analysis United States/epidemiology
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Bilimoria Karl Y
Division of Surgical Oncology, Department of Surgery, Northwestern University, Chicago, Illinois, USA.
Bentrem David J
Ko Clifford Y
Tomlinson James S
Stewart Andrew K
Winchester David P
Talamonti Mark S
Article Info
Journal
Cancer
Abbr.
Cancer
ISSN
0008-543X
Published
2007-09-15
Pages
1227-34
Language
English
Region
United States
NLM ID
0374236
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com